Full Press Release Details
Cellect Biotechnology to Present at the
2020 Cell & Gene Meeting on the Mesa
Management to Highlight Progress in Bone
Marrow Transplant (BMT) and Chimeric Antigen Receptor T Cell (CAR T) Business Collaborations
Tel Aviv, Israel September 21, 2020
- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional
selection of cells facilitating safer and more efficacious cell and gene therapies, today announced that the leadership will be
presenting at the Cell & Gene Meeting on the Mesa, which is being held from October 12th - 16th. In addition to providing
an overview of the Company, the management team will provide a progress update on the clinical and development programs and an
overview of the Company's business strategy. Management will be virtually meeting cell and gene therapy companies to support collaborations.
"This is one of the most prestigious
meetings for our industry, and despite it being virtual this year due to the COVID-19 pandemic, it will not dampen our enthusiasm"
commented Dr. Yarkoni. We have successfully adjusted our operations, and we continue to make significant progress with our Israel
and U.S.-based clinical trials. We are also taking meaningful steps to accelerate nearer-term revenue opportunities as we are collaborating
with several partners that are looking to leverage our technology platform to help improve their products, especially in high-growth
areas such as CAR T, NK (natural killers) and MSC's. We are looking forward to sharing the progress we have made and also
look forward to meeting with current and potential partners developing cell and gene therapies."
To schedule a meeting with the Company's
Chief Executive Officer, Dr. Shai Yarkoni or Chief Operating Officer, Amos Ofer, please request a meeting through the meeting portal
and/or contact the Company direct at shai@cellect.co or amoso@cellect.co. The presentation will be available on the Company's
website prior to the commencement of the meeting. The Cell & Gene Meeting on the Mesa is the sector's foremost annual
conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures.
About Cellect Biotechnology Ltd.
Cellect Biotechnology (APOP) has developed
a breakthrough technology, for the functional selection of cells that aims to improve the robustness, safety and efficacy of a
variety of cell and gene therapies. The Company's technology can be used by researchers, clinical community and pharma companies
in a wide variety of applications including next generation Car T, NK, MSC and gene therapies.
The Company is also developing its own
product that is an improved BMT which is in a current clinical trial for cancer treatment.
Forward Looking Statements
This press release contains forward-looking
statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of
forward-looking words such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of these words or other comparable words or by
the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in
this press release when we discuss Cellect's expectations regarding timing of the commencement of its planned U.S. clinical trial
and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations
of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results
to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from
scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical
results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors,
among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's
history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable
terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working
capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and
clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community;
difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting
from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations;
the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate
its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's
industry; unforeseen scientific difficulties may develop with the Company's technology; the Company's ability to retain or attract
key employees whose knowledge is essential to the development of its products; and the Company's ability to pursue any strategic
transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks
only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking
statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable
securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading
"Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019
filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the
Company's periodic filings with the SEC.
Cellect Biotechnology Ltd.
Eyal Leibovitz, Chief Financial Officer